How long does it take for Teclistamab-cqyv to start taking effect?

Teritusumab (Teclistamab-cqyv) is a bispecific T cell-linked antibody targetingBCMA (B cell maturation antigen) and CD3. It is currently mainly used to treat patients with relapsed or refractory multiple myeloma. The core mechanism of this new type of immunotherapy is to guide T cells directly to malignant plasma cells to achieve precise elimination of tumor cells. Regarding its onset time, clinical observations and international research results show that teritusumab has a relatively rapid onset of efficacy.

Generally, patients experience clinical responses within days to weeks after treatment with teritusumab. Since its mechanism is to attack tumor cells by activating the patient's own T cells, some patients may experience immune-related reactions, such as cytokine release syndrome (CRS) or mild fever, within 3-7 days after the first round of administration. These are often early manifestations of immune system activation and a signal that the drug begins to work. This rapid onset of action is particularly important in the treatment of multiple myeloma, as patients often experience failure of multiple lines of treatment and urgently need timely and effective disease control.

In addition, research data shows that during the treatment of teritusumab, some patients can observe a decrease in tumor load within 14 days after receiving the first full dose, which is reflected in a decrease in M protein levels, a decrease in the proportion of bone marrow plasma cells, or an improvement in imaging. However, it should be pointed out that not all patients take effect within the same time frame, and the efficacy is closely related to individual immune status, disease severity, and previous treatment experience. Some patients may not begin to show clear therapeutic effects until the first month of treatment.

In short, as an innovative immunotherapy drug, teritusumab has a relatively rapid onset of action and often shows clinical response after the first round or the first few rounds of treatment. However, the evaluation of drug efficacy requires the integration of multiple factors and cannot be judged solely by early changes in symptoms. It is recommended that patients complete the entire dosing cycle under the guidance of a professional doctor in order to accurately judge the efficacy and obtain sustained clinical benefits.

Reference materials:https://www.tecvayli.com/